Literature DB >> 8435602

Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep).

H L Janssen1, J T Brouwer, F Nevens, J M Sanchez-Tapias, A Craxi, S Hadziyannis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8435602      PMCID： PMC1676631          DOI： 10.1136/bmj.306.6870.107

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Liver failure due to recombinant alpha interferon.

Authors:  J M Durand; G Kaplanski; I Portal; C Scheiner; Y Berland; J Soubeyrand
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

2.  A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  R P Perrillo; E R Schiff; G L Davis; H C Bodenheimer; K Lindsay; J Payne; J L Dienstag; C O'Brien; C Tamburro; I M Jacobson; R Sampliner; D Feit; J Lefkowitch; M Kuhns; C Meschievitz; B Sanghvi; J Albrecht; A Gibas
Journal:  N Engl J Med       Date:  1990-08-02       Impact factor: 91.245

3.  Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis.

Authors:  I S Sheen; Y F Liaw; D I Tai; C M Chu
Journal:  Gastroenterology       Date:  1985-10       Impact factor: 22.682

4.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245
  4 in total
  8 in total

Review 1.  Diabetes mellitus during interferon therapy for chronic viral hepatitis.

Authors:  Ali Mofredj; Mehran Howaizi; Denis Grasset; Henri Licht; Sylvie Loison; Bruno Devergie; Renato Demontis; Jean-François Cadranel
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 2.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

3.  Low dose alpha interferon therapy can be effective in chronic active hepatitis C. Results of a multicentre, randomised trial.

Authors:  J M Sánchez-Tapias; X Forns; S Ampurdanés; L Titó; R Planas; J M Viver; D Acero; M Torres; P Mas; R Morillas; M Forné; J Espinós; J M Llovet; J Costa; E Olmedo; F X López-Labrador; M T Jiménez de Anta; J Rodés
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

4.  Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report.

Authors:  Yuka Suzuki; Hiroshi Yotsuyanagi; Chiaki Okuse; Yoshihiko Nagase; Hideaki Takahashi; Kyoji Moriya; Michihiro Suzuki; Kazuhiko Koike; Shiro Iino; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

5.  The Role of Interferon in Hepatitis B Therapy.

Authors:  Vincent Rijckborst; Harry L A Janssen
Journal:  Curr Hepat Rep       Date:  2010-08-26

Review 6.  Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.

Authors:  M Haria; P Benfield
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

Review 7.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 8.  Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg).

Authors:  Satinder P Kaur; Arslan Talat; Hamidreza Karimi-Sari; Andrew Grees; Hao Wei Chen; Daryl T Y Lau; Andreea M Catana
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.